natgillin/translations-raw huggingface dataset:
Elevations in aminotransferases were associated with elevated bilirubin ( 2  ULN) without evidence of biliary obstruction in 0.2% (5 patients) on bosentan and 0.3% (6 patients) on placebo.
Zvišanja aminotransferaz so bila povezana z zvišanjem bilirubina ( 2  ZMN) brez znakov biliarne obstrukcije pri 0,2 % (5 bolnikih) na bosentanu in 0,3 % (6 bolnikov) na placebu.
Elevations in aspartate aminotransferase, mainly mild to moderate.
Zvišanje aspartat- aminotransferaze, v glavnem blago do zmerno
elevations in blood tests of liver function (transaminases)
zvišane vrednosti krvnih preiskav delovanja jeter (transaminaze),
Elevations in cholesterol were of grade 3-4 intensity.
Zvišanje vrednosti holesterola je bilo stopnje 3–4.
Elevations in hepatic enzymes have been observed with the use of Plegridy.
Povišanje jetrnih encimov so opazili z uporabo zdravila Plegridy.
Elevations in lactate dehydrogenase and alkaline phosphatase1; Transient elevations in LFT's for ALT or AST1
zvišanje laktat- dehidrogenaze in alkalne fosfataze1, prehodno zvišanje jetrnih funkcijskih testov za ALT ali AST1
Elevations in lipid parameters including total cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL) and triglycerides were observed in patients treated with tocilizumab (see section 4.8).
Pri bolnikih, ki so dobivali tocilizumab so opazili zvišanje vrednosti lipidov, vključno z zvišanjem celotnega holesterola, lipoproteina majhne gostote (LDL), lipoproteina velike gostote (HDL) in trigliceridov (glejte poglavje 4.8).
Elevations in lipid parameters responded to treatment with lipid-lowering agents.
Zvišanje vrednosti lipidov se je odzvalo na zdravljenje s hipolipemiki.
Elevations in serum creatine kinase activity
povečanje aktivnosti serumske kreatin kinaze
Elevations in total bilirubin, mainly mild to moderate.
Zvišanje celotnega bilirubina, v glavnem blago do zmerno
Elevations in triglycerides and cholesterol (lipid parameters) were observed in patients treated with SYLVANT (see section 4.8).
Pri bolnikih, ki so prejemali zdravilo SYLVANT, so opažali zvišanje koncentracij trigliceridov in holesterola (glejte poglavje 4.8).
Elevations in uric acid
zvišanje sečne kisline
Elevations of alanine aminotransferase and aspartate aminotransferase (>5 times ULN), were reported in 1% and <1% of placebo-treated patients and 2% and <1% of patients treated with Plegridy respectively.
Zvišanja alanin-aminotransferaze in aspartat-aminotransferaze (> 5-kratna ULN), so opazili pri 1 % oz. < 1 % bolnikov, zdravljenih s placebom, in 2 % oz. < 1 % bolnikov, zdravljenih z zdravilom Plegridy.
Elevations of ALT to ≥3XULN occurred in 0.7% (7/935) of Vimpat patients and 0% (0/356) of placebo patients.
Povišane vrednosti ALT na ≥ 3x zgornjo mejo normalnih vrednosti (ULN), so se pojavile pri 0,7 % (7/935) bolnikov, ki so jemali zdravilo Vimpat, in pri 0% (0/356) bolnikov, ki so jemali placebo.
Elevations of ALT/AST > 5 x ULN were observed in 0.7% of tocilizumab monotherapy patients and 1.4% of tocilizumab plus DMARD patients, the majority of whom were discontinued permanently from tocilizumab treatment.
Zvišanje ALT/AST na > 5-kratno ZMN so opažali pri 0,7 % bolnikov, ki so dobivali tocilizumab v monoterapiji, in pri 1,4 % bolnikov, ki so tocilizumab dobivali v kombinaciji z imunomodulirajočimi antirevmatičnimi zdravili; pri večini teh so zdravljenje s tocilizumabom ukinili.
Elevations of AST and/or ALT are associated with sitaxentan sodium.
S natrijev sitaksentanat so povezane zvišane vrednosti AST in/ali ALT.
Elevations of CPK
zvišanje CPK
Elevations of GGT to greater than five times ULN were observed in 4 % of all patients treated with 600 mg of efavirenz and 1.5 - 2 % of patients treated with control regimens (7 % of efavirenz-treated patients and 3 % of control-treated patients after long-term treatment).
Povišanja GGT na več kot petkratno ZMN so opazili pri 4 % vseh bolnikov, zdravljenih s 600 mg efavirenza, in pri 1,5–2 % bolnikov, na kontrolnem režimu (po dolgotrajnem zdravljenju pri 7 % bolnikov, zdravljenih z efavirenzem, in 3 % bolnikov, na kontrolnem režimu).
Elevations of GGT to greater than five times ULN were observed in 4% of all patients treated with 600 mg of efavirenz and 1.5-2% of patients treated with control regimens (7% of efavirenz-treated patients and 3% of control-treated patients after long-term treatment).
Povišanja (GGT) na več kot petkratno ZMN so opazili pri 4 % vseh bolnikov, zdravljenih s 600 mg efavirenza, in pri 1,5–2 % bolnikov, na kontrolnem režimu (po dolgotrajnem zdravljenju pri 7 % bolnikov, zdravljenih z efavirenzem, in 3 % bolnikov, na kontrolnem režimu).
Elevations of GGT to greater than five times ULN were observed in 4% of all patients treated with 600 mg of efavirenz and 1.5-2% of patients treated with control regimens (7% of efavirenz-treated patients and 3% of control-treated patients after long-term treatment).
Povišanja GGT na več kot petkratno ZMN so opazili pri 4 % vseh bolnikov, zdravljenih s 600 mg efavirenza, in pri 1,5–2 % bolnikov, na kontrolnem režimu (po dolgotrajnem zdravljenju pri 7 % bolnikov, zdravljenih z efavirenzem, in 3 % bolnikov, na kontrolnem režimu).
elevations of hepatic
zvišanja jetrnih aminotransferaz
elevations of hepatic aminotransferases (ALT,
Prehodna asimptomatska zvišanja jetrnih aminotransferaz (ALT, AST), posebno na začetku zdravljenja (glejte poglavje 4.4)
elevations of hepatic aminotransferases (ALT, AST),
prehodna asimptomatska zvišanja jetrnih aminotransferaz (ALT, AST),
Elevations of neutrophil counts are dose-dependent at recommended doses.
Povečanje števila nevtrofilcev je pri priporočenih odmerkih odvisno od odmerka.
Elevations of serum transaminases and severe hepatic injury have occurred in patients treated with Zinbryta (see section 4.8).
Pri bolnikih, zdravljenih z zdravilom Zinbryta, je prišlo do povišanja serumskih transaminaz in hudih poškodb jeter (glejte poglavje 4.8).
Elevations of serum transaminases and severe hepatic injury have occurred in patients treated with Zinbryta.
Pri bolnikih, zdravljenih z zdravilom Zinbryta, je prišlo do povišanja serumskih transaminaz in hudih poškodb jeter.
Elevations of serum transaminases can occur during treatment with Esbriet.
Med zdravljenjem z zdravilom Esbriet se lahko poviša raven transaminaz v serumu.
Elevations of transaminases, particularly in the setting of concomitant increases in bilirubin, may be an early indication of drug-induced liver injury and these patients should be managed appropriately (see sections 4.2 and 4.8).
Povečane vrednosti transaminaz, še zlasti ob sočasnem povečanju vrednosti bilirubina, so lahko zgodnji znak poškodb jeter, povzročenih z zdravilom; te bolnike je treba ustrezno obravnavati (glejte poglavji 4.2 in 4.8).
Elevations to  8  ULN were seen in 3.6% of the bosentan- treated patients and 0.4% of the placebo-treated patients.
Zvišanja do  8  ZMN so opazili pri 3,6 % bolnikov, ki so jemali bosentan, in 0,4 % bolnikov, ki so prejemali placebo.
Elevations to  8  ULN were seen in 3.6% of the bosentan-treated patients and 0.4% of the placebo-treated patients.
Zvišanja do  8  ZMN so opazili pri 3,6 % bolnikov, ki so jemali bosentan, in 0,4 % bolnikov, ki so prejemali placebo.
Eleven (21%) patients had an increase from Baseline in QTcF value ≥30 to <60 msec and 1 (2%) patient had an increase from Baseline in QTcF value of ≥60 msec.
Vrednost QTcF se je glede na izhodišče pri enem bolniku (2 %) zvišala za ≥ 60 ms, pri 11 bolnikih (21 %) pa za ≥ 30 ms do < 60 ms.
Eleven patients achieved rapid CHR; ten had complete resolution of cytogenetic abnormalities and a decrease or disappearance of fusion transcripts as measured by RT-PCR.
11 bolnikov je doseglo hiter popolni hematološki odziv, pri desetih je prišlo do popolne normalizacije citogenetičnih nepravilnosti in zmanjšanja oziroma izginotja fuzijskih transkriptov, kot so izmerili z verižno reakcijo s polimerazo v realnem času (RT- PCR).
Eleven percent of children (5/46) treated for 24 weeks and 13 % of children (6/48) treated for 48 weeks were observed to have a decrease from pre treatment baseline > 30 height for age percentiles to the end of the 5 year long term follow-up.
Pri enajstih odstotkih otrok (5/46), zdravljenih 24 tednov, in 13 % otrok (6/48), zdravljenih 48 tednov, so od časa pred zdravljenjem do konca 5-letnega dolgoročnega spremljanja opazili zmanjšanje > 30 percentilov telesne višine za starost.
Eleven percent of patients enrolled had an ECOG performance score of 2; 70% had radiographic evidence of disease progression with or without PSA progression; 70% had received one prior cytotoxic chemotherapy and 30% received two.
Enajst odstotkov vključenih bolnikov je na lestvici ocenjevanja stanja zmogljivosti ECOG doseglo oceno 2; pri 70% je bilo napredovanje bolezni radiografsko potrjeno skupaj z zviševanjem vrednosti PSA ali brez njega; 70% bolnikov je predhodno prejelo po eno citotoksično kemoterapijo, 30% pa po dve.
Eleven subjects were reported to have received anti-haemorrhagic agents (eg. rFVIIa, activated prothrombin-complex concentrate, tranexamic acid) prior to first treatment with OBIZUR.
Enajst preiskovancev je pred prvim zdravljenjem z zdravilom OBIZUR prejelo antihemoragike (npr. rFVIIa, koncentrat aktiviranega protrombinskega kompleksa, traneksamsko kislino).
elf-adhesive, paper label - Pramipexole Teva 0.18 mg tablets
Samolepilna papirnata nalepka – Pramipeksol Teva 0,18 mg tablete
elf-adhesive, paper label - Pramipexole Teva 0.7 mg tablets
Samolepilna papirnata nalepka – Pramipeksol Teva 0,7 mg tablete
Eli Lilly and Company (Ireland) Limited Tel: + 353 (0) 1 661 4377
Eli Lilly România S.R.L. Tel: + 40 21 4023000
Eli Lilly and Company (Ireland) Limited Tel: + 353-(0) 1 661 4377
Eli Lilly and Company (Ireland) Limited Tel.: + 353-(0) 1 661 4377
Eli Lilly and Company (Ireland) Limited Tel: + 353-(0) 1 661 4377
Tel: +43-(0) 1 711 780
Eli Lilly and Company Limited Elanco Animal Health Priestley Road
Eli Lilly and Company Ltd Elanco Animal Health Priestley Road
Eli Lilly and Company Limited Elanco Animal Health Priestley Road
Eli Lilly and Company Ltd Elanco Animal Health Priestley Road Basingstoke
Eli Lilly and Company Limited Tel: + 44-(0) 1256 315000
Eli Lilly and Company Limited Tel.: + 44-(0) 1256 315000
Eli Lilly and Company Limited Tel: + 44-(0) 1256 315000
Eli Lilly and Company Limited Tel: +44 (0) 1256 315999
Eli Lilly Benelux S.A./N.V. Tél/Tel: + 32 (0) 2 548 84 84
Eli Lilly Benelux S.A./N.V Tél/Tel: + 32-(0)2 548 84 84
Eli Lilly Benelux S.A./N.V. Tél/Tel: + 32-(0)2 548 84 84
Eli Lilly Benelux S.A./N.V. Tél/Tel: + 32-(0) 2 548 84 84
Eli Lilly Benelux S.A./N.V. Tél/Tel: + 32-(0)2 548 84 84
Tél/Tel: + 32-(0)2 548 84 84
Eli Lilly Ges.m.b.H.
Eli Lilly and Company (Ireland) Limited.
Eli Lilly Holdings Limited atstovybė Tel. +370 (5) 2649600
Eli Lilly Holdings Limited atstovybė Tel.: +370 (5) 2649600
Eli Lilly Holdings Limited atstovybė Tel: + 370 (5) 2649600
ΦΑΡΜΑΣΕΡΒ-ΛΙΛΛΥ Α.Ε.Β.Ε. Τηλ: + 30 210 629 4600
Eli Lilly Holdings Limited Eesti filiaal Tel: +372 6 817 280
Eli Lilly Holdings Limited Eesti filiaal Tel.: +372 6 817 280
Eli Lilly Holdings Limited pārstāvniecība Latvijā Tel: + 371 67364000
Eli Lilly Holdings Limited pārstāvniecība Latvijā Tel: + 371 7364000
Eli Lilly Holdings Limited pārstāvniecība Latvijā Tel: +371 67364000
Eli Lilly Holdings Limited pārstāvniecība Latvijā Tel.: +371 67364000
Eli Lilly Holdings Limited, pārstāvniecība Latvijā Tel: + 371 67364000
Eli Lilly Holdings Limited, pārstāvniecība Latvijā
Eli Lilly Hrvatska d.o.o.
Eli Lilly Holdings Limited.
Eli Lilly Italia S.p.A. Tel: + 39- 055 42571
Eli Lilly Italia S.p.A.
Eli Lilly Italia S.p.A. Tel: + 39- 055 42571
Eli Lilly Italia S.p.A. Tel.: + 39- 055 42571
Eli Lilly Italia S.p.A. Tel: + 39- 055 42571
Tel: + 34 91 663 5000
Eli Lilly Italia S.p.A., Via A. Gramsci 731-733, 50019 Sesto Fiorentino, Florence, Italy,
Eli Lilly Italia S.p.A., Via A. Gramsci 731-733, 50019 Sesto Fiorentino, Firence, Italija,
Eli Lilly Italia S.p.A., Via A. Gramsci 731-733, 50019 Sesto Fiorentino, Florence, Italy.
Eli Lilly Italia S.p.A., Via A. Gramsci 731-733, 50019 Sesto Fiorentino, Firence, Italija.
Eli Lilly Italia S.p.A., Via Gramsci 731-733, 50019 Sesto Fiorentino, (FI) Italy,
Eli Lilly Italia S.p.A., Via Gramsci 731-733, 50019 Sesto Fiorentino, (FI) Italija,
Eli Lilly Italia S.p.A.,Via Gramsci 731/733, 50019, Sesto Fiorentino, Firenze (FI), Italy
Eli Lilly Italia S.p.A.,Via Gramsci 731/733, 50019, Sesto Fiorentino, Firenze (FI), Italija
Eli Lilly Nederland B V., Papendorpseweg 83, 3528 BJ Utrecht, The Netherlands.
Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, Nizozemska.
Eli Lilly Nederland B.V. Papendorpseweg 83, 3528 BJ Utrecht The Netherlands
Eli Lilly Nederland B.V Papendorpseweg 83, 3528 BJ Utrecht Nizozemska
Eli Lilly Nederland B.V. Tel: + 31-(0) 30 60 25 800
Eli Lilly Nederland B.V. Tel.: + 31-(0) 30 60 25 800
Eli Lilly Nederland B.V. Tel: + 31-(0) 30 60 25 800
Eli Lilly Nederland, B.V. Tel: + 31-(0) 30 60 25 800
Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, The Netherlands.
Eli Lilly Nederland BV, Papendorpseweg 83, 3528 BJ Utrecht, Nizozemska.
Eli Lilly Norge A.S Tlf: + 47 22 88 18 00
Tel: + 48 (0) 22 440 33 00
Eli Lilly Norge A.S. Tlf: + 47 22 88 18 00
Tel: + 34 91-663 50 00
Eli Lilly Norge A.S. Tlf: +47 22 88 18 00
Eli Lilly Holdings Limited Eesti filiaal Tel: +372 6 817 280
Eli Lilly Regional Operations GmbH., Kölblgasse 8-10, 1030, Vienna, Austria.
Eli Lilly Regional Operations GmbH., Kölblgasse 8-10, 1030, Vienna, Avstrija.
Eli Lilly România S.R.L. Tel: + 40 21 4023000
Charles de Giorgio Ltd.
Eli Lilly România S.R.L. Tel: + 40 21 4023000
Eli Lilly and Company (Ireland) Limited Tel: + 353 (0) 1 661 4377
Eli Lilly România S.R.L. Tel: + 40 21 4023000
Eli Lilly Ges. m.b.H.
Eli Lilly România S.R.L. Tel: + 40 21 4023000
Eli Lilly România S.R.L. Tel.: + 40 21 4023000
Eli Lilly România S.R.L. Tel: + 40 21 4023000
Tel: + 386 (0)1 580 00 10
Eli Lilly S.A. Dunderrow Kinsale County Cork Ireland
Eli Lilly S.A. Dunderrow Kinsale County Cork Irska
Eli Lilly Sweden AB Tel: + 46 (0) 8 7378800
Eli Lilly Holdings Limited pārstāvniecība Latvijā Tel: + 371 7364000
Eli Lilly Sweden AB Tel: + 46-(0) 8 7378800
Eli Lilly Sweden AB Tel.: + 46-(0) 8 7378800
Eli Lilly Sweden AB Tel: + 46-(0) 8 7378800
Eli Lilly Sweden AB Tel: + 46-(0) 8 737 88 00
Eligible for efficacy analysis, n
Bolniki, primerni za analizo učinkovitosti, n
Eligible patients for these trials had chronic hepatitis C confirmed by a positive HCV- RNA polymerase chain reaction assay (PCR) (> 30 IU/mL), a liver biopsy consistent with a histological diagnosis of chronic hepatitis with no other cause for the chronic hepatitis, and abnormal serum ALT.
V ta klinična preskušanja so vključili bolnike s kroničnim hepatitisom C, potrjenim s pozitivnim izvidom testa polimerazne verižne reakcije (PCR) na HCV-RNA (> 30 i.e./ml), izvid jetrne biopsije pa je bil v skladu s histološko diagnozo kroničnega hepatitisa brez drugih vzrokov za kronični hepatitis, poleg tega pa so imeli bolniki tudi nenormalne serumske vrednosti ALT.
Eligible patients for these trials had chronic hepatitis C confirmed by a positive HCV-RNA polymerase chain reaction assay (PCR) (> 100 copies/ml), a liver biopsy consistent with
Bolniki, primerni za vključitev v te raziskave, so imeli kronični hepatitis C, ki je bil potrjen s pozitivnim izvidom testa polimerazne verižne reakcije za HCV-RNA (PCR) (> 100 kopij/ml), izvidom jetrne biopsije, ki je histološko potrdil diagnozo kroničnega hepatitisa brez drugega vzroka za kronični hepatitis, ter nenormalno serumsko vrednostjo ALT.
Eligible patients for this study were to have biopsy-proven HGD in Barrett’s oesophagus (BO).
Bolniki, primerni za to raziskavo, so morali imeti z biopsijo potrjeno HGD v Barrettovem požiralniku (BP).
Eligible patients had persistent, recurrent or metastatic squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix which was not amenable to curative treatment with surgery and/or radiation therapy and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor–targeted agents.
Primerne bolnice so imele histološko skvamozni karcinom, adenoskvamozni karcinom ali adenokarcinom materničnega vratu, pri katerem ni bila možna ozdravitev z operacijo in/ali obsevanjem, ponovitev bolezni ali metastatsko bolezen ter predhodno še niso bile zdravljene z bevacizumabom ali drugimi zaviralci VEGF ali tarčnimi učinkovinami za receptor VEGF.
Eligible patients had received chemotherapy for malignancy or had undergone hematopoietic stem-cell transplantation, and presented with neutropaenia (<500 cells/mm3 for 96 hours) and fever (>38.0°C) not responding to ≥96 hours of parenteral antibacterial therapy.
Za študijo ustrezni bolniki so dobivali kemoterapijo zaradi malignoma ali so prestali presaditev hematopoetskih matičnih celic ter so imeli nevtropenijo (< 500 celic/mm3 96 ur) in zvišano telesno temperaturo (> 38.0 °C), ki se nista odzivali na ≥ 96-urno parenteralno protibakterijsko terapijo.
Eligible patients were randomised in a 1:1 ratio to receive either Empliciti in combination with lenalidomide and dexamethasone or lenalidomide and dexamethasone.
Primerni bolniki so bili v razmerju 1:1 randomizirani na zdravljenje z zdravilom Empliciti v kombinaciji z lenalidomidom in deksametazonom ali zdravljenje z lenalidomidom in deksametazonom.
Eligible patients were randomized (1:1:1:1) to placebo or one of three fixed levodopa/carbidopa doses of 145 mg/36.25 mg,
Primerne bolnike so randomizirali (1 : 1 : 1 : 1) v skupine, ki so prejemale placebo ali enega izmed treh fiksnih odmerkov levodope/karbidope, in sicer 145 mg/36,25 mg,
Eliglustat is also contraindicated in patients who are CYP2D6 poor metabolisers taking a strong CYP3A inhibitor.
Eliglustat je kontraindiciran tudi pri bolnikih, ki so slabi presnavljalci encima CYP2D6 in jemljejo kakšen močan zaviralec CYP3A.
Eliglustat is contraindicated in patients who are CYP2D6 Intermediate Metabolisers or Extensive Metabolisers who are taking a strong or moderate CYP2D6 inhibitor concomitantly with a strong or moderate CYP3A inhibitor.
Eliglustat je kontraindiciran pri bolnikih, ki so vmesni ali hitri presnavljalci encima CYP2D6 in jemljejo kakšen močan ali zmeren zaviralec CYP2D6 hkrati z močnim ali zmernim zaviralcem CYP3A.
Eliglustat should not be used concomitantly with medicines that may have an impact on liver enzymes that play a role in the metabolism of eliglustat.
Eliglustata se ne sme uporabljati hkrati z zdravili, ki bi lahko vplivala na jetrne encime, udeležene v presnovi eliglustata.
Elimination
Huda kožna obolenja
Elimination
Izlocanje
Elimination
Izločanje:
Elimination
Odstranjevanje iz telesa
Elimination
placebo
Elimination
Porazdelitev
Elimination and half-Life
Izločanje in razpolovni čas
Elimination appears monophasic with a half-life of about 4 hours after a single-subcutaneous dose to about 7 hours after repeated dosing.
Kaže, da je izločanje monofazno, saj znaša razpolovni čas od približno 4 ur po uporabi posamičnega subkutanega odmerka do približno 7 ur po večkratni uporabi.
Elimination half-life (h)
Razpolovni čas izločanja (h)
Elimination half-life is long – approximately 5.5 days.
Razpolovna doba izločanja je dolga – približno 5,5 dni.
Elimination half-life is long – approximately 6.9 days.
Razpolovna doba izločitve je dolga – približno 6,9 dni.
Elimination is primarily via faeces with renal elimination accounting for < 4 % of the administered dose.
Izločanje v glavnem poteka preko blata, preko ledvic se izloči manj kot 4 % uporabljenega odmerka.
Elimination of A771726 is slowand characterised by an apparent clearance of about 31 ml/hr.
Izločanje A771726 je počasno, z navideznim očistkom približno 31 ml/uro.
Elimination of fleas within 24 hours.
Eliminacija bolh v 24 urah.
Elimination of selexipag is predominantly via metabolism with a mean terminal half-life of 0.8–2.5 h.
Seleksipag se pretežno izloča s presnovo in ima povprečen končni razpolovni čas 0,8–2,5 h.
Elimination of ticks within 48 hours.
Eliminacija klopov v 48 urah.
Elimination of valdecoxib is by extensive hepatic metabolism involving multiple pathways, including cytochrome P 450 (CYP) 3A4 and CYP2C9 isoenzymes and glucuronidation (about 20%) of the sulphonamide moiety.
Izločanje valdekoksiba poteka z obsežno presnovo v jetrih, ki vključuje več poti, med drugim izoencima CYP3A4 in CYP2C9 citokroma P450 ter glukuronidacijo (približno 20 %) sulfonamidne skupine.
Elimination rate is markedly lower than in older children and adults, with an elimination half-life estimated at approximately 30 hours (16–43).
Hitrost izločanja zdravila iz telesa je znatno manjša kot pri starejših otrocih in odraslih, razpolovni čas odstranjevanja iz telesa ocenjujejo na približno 30 ur (16-43).
Elimination studies in dogs have shown that 29.8% and 44% of the dose were excreted in urine and faeces, respectively by 14 days following dosing.
Eliminacijske študije pri psih so kazale, da se je 29,8 % oziroma 44 % odmerkov izločilo prek urina in blata v 14 dneh po dajanju odmerka.
elimination via alcohol
preko alkoholne
Elimination was absorption rate limited (flip-flop kinetics), which explains the longer t½ after transdermal patch (3.4 h) versus oral or intravenous administrations (1.4 to 1.7 h).
Izločanje je omejeno s hitrostjo absorpcije (flip- flop učinek), kar pojasnjuje daljši t½ pri uporabi transdermalnih obližev (3,4 ure) v primerjavi s peroralnim ali intravenskim odmerjanjem (1,4 do 1,7 ure).
Elimination: After subcutaneous bolus administration, the mean terminal half-life t½ of somatropin is about 2.3 hours.
Izločanje: Po subkutani bolusni aplikaciji je povprečni končni razpolovni čas t1/2 somatropina približno 2,3 ure.
Elimination: Clearance of enfuvirtide after intravenous administration 90 mg was 1.4  0.28 l/h and the elimination half-life was 3.2  0.42 h.
Izločanje: očistek enfuvirtida po intravenskem dajanju 90 mg je bil 1,4  0,28 l/h, razpolovni čas izločanja je bil 3,2  0,42 h.
Elimination: Erlotinib is excreted predominantly as metabolites via the faeces (>90%) with renal elimination accounting for only a small amount (approximately 9%) of an oral dose.
Izločanje: erlotinib se po peroralnem dajanju v glavnem izloča v obliki presnovkov z blatom (> 90 %), v manjšem obsegu pa tudi prek ledvic (približno 9 %).
Elimination: following a single 400 mg dose of 14C-atazanavir, 79% and 13% of the total radioactivity was recovered in the faeces and urine, respectively.
Izločanje: po enkratnem 400-mg odmerku s 14C- označenega atazanavirja se je 79% radioaktivnosti pojavilo v blatu in 13% v urinu.
Elimination: Memantine is eliminated in a monoexponential manner with a terminal t½ of 60 to 100 hours.
Izločanje: Memantin se izloča na monoekspotencialni način s končnim razpolovnim časom (t½) 60 do 100 ur.
Elimination: Memantine is eliminated in a monoexponential manner with a terminal t½ of 60 to100 hours.
Izločanje: Memantin se izloča na monoekspotencialni način s končnim razpolovnim časom (t½) 60 do 100 ur.
Elimination‌‌‌‌‌
Izločanje
Eliquis (apixaban) is an oral anticoagulant acting by direct selective inhibition of factor Xa.
Zdravilo Eliquis (apiksaban) je peroralni antikoagulant, ki deluje tako, da neposredno selektivno zavira faktor Xa.
Eliquis 2.5 mg film-coated tablets
Eliquis 2,5 mg filmsko obložene tablete
Eliquis 2.5 mg film-coated tablets
Eliquis 2,5 mg filmsko obložene tablete apiksaban
Eliquis 2.5 mg film-coated tablets apixaban
Eliquis 2,5 mg filmsko obložene tablete apiksaban
Eliquis 5 mg film-coated tablets
Eliquis 5 mg filmsko obložene tablete
Eliquis 5 mg film-coated tablets
Eliquis 5 mg filmsko obložene tablete apiksaban
Eliquis 5 mg film-coated tablets apixaban
Eliquis 5 mg filmsko obložene tablete apiksaban
Eliquis can be taken with or without food.
Zdravilo Eliquis lahko jemljete s hrano ali brez nje.
Eliquis contains lactose (a type of sugar).
Zdravilo Eliquis vsebuje laktozo (vrsta sladkorja).
Eliquis contains the active substance apixaban and belongs to a group of medicines called anticoagulants.
Zdravilna učinkovina zdravila Eliquis je apiksaban, ki sodi v skupino zdravil, imenovano antikoagulanti.